Morgan Stanley Upgrades West Pharmaceutical Servs to Overweight, Raises Price Target to $400
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsUpgradesPrice Target
Morgan Stanley analyst Kallum Titchmarsh upgrades West Pharmaceutical Servs (NYSE:WST) from Equal-Weight to Overweight and raises the price target from $365 to $400.
Morgan Stanley analyst Kallum Titchmarsh upgrades West Pharmaceutical Servs (NYSE:WST) from Equal-Weight to Overweight and raises the price target from $365 to $400.